Tong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tong Xu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Minghua Ge
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
3 shared publications Ping Huang
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou China
3 shared publications- Ping Huang
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou 310014, China
3 shared publications Yiwen Zhang
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou China
3 shared publications- Yiwen Zhang
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China
3 shared publications Feifeng Song
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou China
2 shared publications
Latest Publications
- 6 July 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (13) , e72118
Rational Inhibitor Discovery for BRAF V600E Using PSeMut , a Sequence‐Driven Model
Mutational heterogeneity at drug targets both undermines small‐molecule efficacy and contributes to disease. A practical response is to discover scaffolds that maintain potency in the presence of mutations; however, prevailing biological research strategies are not readily scalable, constraining high‐throughput design and discovery. We present PSeMut, a structure‐free Siamese model that contrasts wild‐type and mutant protein‐ligand fingerprints (PSICHIC‐derived) to predict mutation‐induced activity changes. On a variant‐resolved benchmark, PSeMut attains a test RMSE of 0.400 ± 0.025 and consistently outperforms classical baselines trained on identical features and splits; removing the exchange‐consistency constraint degrades performance. To evaluate the feasibility of the framework in a prospective setting, we applied a structure‐free prioritization pipeline—combining scaffold‐novelty filtering, PSICHIC activity scoring, PSeMut‐based mutation‐tolerance ranking, clustering‐based selection, and biological validation. This workflow prioritized SNS‐314 for follow‐up testing. In the selected validation assays, SNS‐314 showed mutation‐selective cellular activity (IC50 = 0.45 μM in BRAF V600E ; 7.5‐fold vs. BRAF WT ), suppressed the BRAF‐MEK–ERK signaling axis, and produced about 50% tumor growth inhibition in vivo without overt toxicity. Together, these results validate the effectiveness of PSeMut in a structure‐free, mutation‐aware screening workflow that links sequence‐driven modeling to experimental confirmation and enables rational prioritization of mutation‐resilient scaffolds across heterogeneous disease settings.
- 6 July 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (13) , e72118
Rational Inhibitor Discovery for BRAF V600E Using PSeMut , a Sequence‐Driven Model
Mutational heterogeneity at drug targets both undermines small‐molecule efficacy and contributes to disease. A practical response is to discover scaffolds that maintain potency in the presence of mutations; however, prevailing biological research strategies are not readily scalable, constraining high‐throughput design and discovery. We present PSeMut, a structure‐free Siamese model that contrasts wild‐type and mutant protein‐ligand fingerprints (PSICHIC‐derived) to predict mutation‐induced activity changes. On a variant‐resolved benchmark, PSeMut attains a test RMSE of 0.400 ± 0.025 and consistently outperforms classical baselines trained on identical features and splits; removing the exchange‐consistency constraint degrades performance. To evaluate the feasibility of the framework in a prospective setting, we applied a structure‐free prioritization pipeline—combining scaffold‐novelty filtering, PSICHIC activity scoring, PSeMut‐based mutation‐tolerance ranking, clustering‐based selection, and biological validation. This workflow prioritized SNS‐314 for follow‐up testing. In the selected validation assays, SNS‐314 showed mutation‐selective cellular activity (IC50 = 0.45 μM in BRAF V600E ; 7.5‐fold vs. BRAF WT ), suppressed the BRAF‐MEK–ERK signaling axis, and produced about 50% tumor growth inhibition in vivo without overt toxicity. Together, these results validate the effectiveness of PSeMut in a structure‐free, mutation‐aware screening workflow that links sequence‐driven modeling to experimental confirmation and enables rational prioritization of mutation‐resilient scaffolds across heterogeneous disease settings.
- 22 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71063
Timosaponin A3 Ameliorates Prostate Cancer Progression via Upregulating STARD4 Mediated Cholesterol Metabolism
Prostate cancer (PCa) is a common and aggressive malignancy in men, often diagnosed at advanced stages with a poor five‐year survival rate. Despite therapeutic advances, effective treatments for castration‐resistant PCa remain lacking. Timosaponin A3 (TA3), a natural steroidal saponin derived from Anemarrhena asphodeloides Bunge, has shown potential anti‐tumor properties, but its role in PCa and the underlying mechanisms have not been fully elucidated. In this study, we demonstrate that TA3 significantly inhibits the proliferation, migration, and invasion of PCa cells in vitro , and suppresses tumor growth in xenograft models. Transcriptomic analysis revealed that TA3 exerts its anti‐tumor effects by modulating cholesterol metabolism. Elevated cholesterol levels were observed in PCa patients, and exogenous cholesterol administration reduced tumor growth in vivo . Notably, TA3 treatment upregulated the lipid transporter StAR related lipid transfer domain containing 4 (STARD4), a key regulator of cholesterol transport, which was confirmed to mediate the inhibitory effects of TA3 on PCa progression. Overexpression of STARD4 attenuated PCa development both in vitro and in vivo , while STARD4 knockdown abolished these effects. Collectively, our findings suggest that TA3 suppresses PCa progression by enhancing cholesterol metabolism via STARD4 upregulation, supporting its potential as a novel therapeutic agent for prostate cancer.
- 22 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71063
Timosaponin A3 Ameliorates Prostate Cancer Progression via Upregulating STARD4 Mediated Cholesterol Metabolism
Prostate cancer (PCa) is a common and aggressive malignancy in men, often diagnosed at advanced stages with a poor five‐year survival rate. Despite therapeutic advances, effective treatments for castration‐resistant PCa remain lacking. Timosaponin A3 (TA3), a natural steroidal saponin derived from Anemarrhena asphodeloides Bunge, has shown potential anti‐tumor properties, but its role in PCa and the underlying mechanisms have not been fully elucidated. In this study, we demonstrate that TA3 significantly inhibits the proliferation, migration, and invasion of PCa cells in vitro , and suppresses tumor growth in xenograft models. Transcriptomic analysis revealed that TA3 exerts its anti‐tumor effects by modulating cholesterol metabolism. Elevated cholesterol levels were observed in PCa patients, and exogenous cholesterol administration reduced tumor growth in vivo . Notably, TA3 treatment upregulated the lipid transporter StAR related lipid transfer domain containing 4 (STARD4), a key regulator of cholesterol transport, which was confirmed to mediate the inhibitory effects of TA3 on PCa progression. Overexpression of STARD4 attenuated PCa development both in vitro and in vivo , while STARD4 knockdown abolished these effects. Collectively, our findings suggest that TA3 suppresses PCa progression by enhancing cholesterol metabolism via STARD4 upregulation, supporting its potential as a novel therapeutic agent for prostate cancer.
- 12 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (12) , e70727
Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma
The poor prognosis of clear cell renal cell carcinoma (ccRCC) is primarily attributed to inherent resistance and malignant progression, yet the underlying mechanism and effective strategies remain poorly understood. Renal drug transporters play an indispensable role in regulating the intracellular concentration of tumor cells. Therefore, this study aims to investigate the role of proton‐coupled oligopeptide transporter 2 (PEPT2) in ccRCC. PEPT2 was found to be downregulated in ccRCC tissues and cell lines, and its low expression was associated with an unfavorable prognosis in ccRCC patients. Overexpression of PEPT2 inhibited cell proliferation and metastasis both in vitro and in vivo. Furthermore, the transcriptional repression of PEPT2 was attributed to DNMT3A/B mediated methylation of its promoter, which could be reversed by the epigenetic inhibitor decitabine, leading to the restored expression and functional transport activity of PEPT2. Importantly, the combination treatment with decitabine (an epigenetic inhibitor) and a lenalidomide‐dipeptide conjugate (a substrate for PEPT2) significantly enhanced cytotoxicity against ccRCC cells both in vitro and in vivo. Our investigation into the epigenetic repression of PEPT2 promoters has revealed a significant role in the progression of ccRCC. Furthermore, our findings demonstrate that the combination of PEPT2‐targeted lenalidomide with epigenetic therapy effectively enhances cytotoxicity in ccRCC cells. This study provides compelling experimental evidence for the potential therapeutic benefit of targeting PEPT2 in the treatment of ccRCC.
- 12 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (12) , e70727
Epigenetic Regulation of PEPT2 as a Novel Strategy to Improve the Antitumor Efficacy of Lenalidomide in Clear Cell Renal Cell Carcinoma
The poor prognosis of clear cell renal cell carcinoma (ccRCC) is primarily attributed to inherent resistance and malignant progression, yet the underlying mechanism and effective strategies remain poorly understood. Renal drug transporters play an indispensable role in regulating the intracellular concentration of tumor cells. Therefore, this study aims to investigate the role of proton‐coupled oligopeptide transporter 2 (PEPT2) in ccRCC. PEPT2 was found to be downregulated in ccRCC tissues and cell lines, and its low expression was associated with an unfavorable prognosis in ccRCC patients. Overexpression of PEPT2 inhibited cell proliferation and metastasis both in vitro and in vivo. Furthermore, the transcriptional repression of PEPT2 was attributed to DNMT3A/B mediated methylation of its promoter, which could be reversed by the epigenetic inhibitor decitabine, leading to the restored expression and functional transport activity of PEPT2. Importantly, the combination treatment with decitabine (an epigenetic inhibitor) and a lenalidomide‐dipeptide conjugate (a substrate for PEPT2) significantly enhanced cytotoxicity against ccRCC cells both in vitro and in vivo. Our investigation into the epigenetic repression of PEPT2 promoters has revealed a significant role in the progression of ccRCC. Furthermore, our findings demonstrate that the combination of PEPT2‐targeted lenalidomide with epigenetic therapy effectively enhances cytotoxicity in ccRCC cells. This study provides compelling experimental evidence for the potential therapeutic benefit of targeting PEPT2 in the treatment of ccRCC.
- 2 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70494
SPP1 ‐ SRD5A3 signaling axis regulated lymph node metastasis by activating Mucin type O glycan biosynthesis
Lymph node metastasis (LNM) holds substantial implications for the recurrence and survival of cancer patients, but the intricate regulatory mechanisms underlying LNM remain poorly understood. MTOGB was dominantly increased in LNM of pan‐cancer, significantly activated in epithelial cells and enriched in LNM. Subsequently, we identified a specific epithelial cell subpopulation, EC4, located at the terminal of the LNM differentiation trajectory Lineage2. By intersecting differentially expressed genes in cluster 2, EC4 and Lineage2, we identified six crucial genes. Notably, the expression of Steroid 5α‐reductase 3 (SRD5A3) increased with the progression of LNM stages. Knockdown of SRD5A3 effectively suppressed the MTOGB, blocking metastasis in both cell and animal models. Nilotinib was screened as a candidate inhibitor of SRD5A3 and was confirmed to remarkably decrease cancer cell metastasis. SOX4 was identified as a potential transcription factor of SRD5A3, modulated by a dramatic increase in cell communication of SPP1 + macrophages in the immune microenvironment. The supernatant from SPP1 + macrophage significantly enhanced the expression of SOX4/SRD5A3 and the metastatic ability of cancer cells, and this effect was reversed by the deletion of SPP1. Collectively, our findings illuminate the SPP1‐SRD5A3 signaling as the crucial driver in LNM and suggest that its blockade could be a promising option for overcoming LNM.
- 2 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70494
SPP1 ‐ SRD5A3 signaling axis regulated lymph node metastasis by activating Mucin type O glycan biosynthesis
Lymph node metastasis (LNM) holds substantial implications for the recurrence and survival of cancer patients, but the intricate regulatory mechanisms underlying LNM remain poorly understood. MTOGB was dominantly increased in LNM of pan‐cancer, significantly activated in epithelial cells and enriched in LNM. Subsequently, we identified a specific epithelial cell subpopulation, EC4, located at the terminal of the LNM differentiation trajectory Lineage2. By intersecting differentially expressed genes in cluster 2, EC4 and Lineage2, we identified six crucial genes. Notably, the expression of Steroid 5α‐reductase 3 (SRD5A3) increased with the progression of LNM stages. Knockdown of SRD5A3 effectively suppressed the MTOGB, blocking metastasis in both cell and animal models. Nilotinib was screened as a candidate inhibitor of SRD5A3 and was confirmed to remarkably decrease cancer cell metastasis. SOX4 was identified as a potential transcription factor of SRD5A3, modulated by a dramatic increase in cell communication of SPP1 + macrophages in the immune microenvironment. The supernatant from SPP1 + macrophage significantly enhanced the expression of SOX4/SRD5A3 and the metastatic ability of cancer cells, and this effect was reversed by the deletion of SPP1. Collectively, our findings illuminate the SPP1‐SRD5A3 signaling as the crucial driver in LNM and suggest that its blockade could be a promising option for overcoming LNM.
- Open Access
- 17 August 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (16) , e70014
Ophiopogonin D′ inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling
Anaplastic thyroid cancer (ATC), an aggressive malignancy with virtually 100% disease‐specific mortality, has long posed a formidable challenge in oncology due to its resistance to conventional treatments and the severe side effects associated with current regimens such as doxorubicin chemotherapy. Consequently, there was urgent need to identify novel candidate compounds that could provide innovative therapeutic strategies for ATC. Ophiopogonin D′ (OPD'), a triterpenoid saponin extracted, yet its roles in ATC has not been reported. Our data demonstrated that OPD' potently inhibited proliferation and metastasis of ATC cells, promoting cell cycle arrest and apoptosis. Remarkably, OPD' impeded growth and metastasis of ATC in vitro and in vivo, displaying an encouraging safety profile. Regulator of G‐protein signalling 4 (RGS4) expression was significantly up‐regulated in ATC compared to normal tissues, and this upregulation was suppressed by OPD' treatment. Mechanistically, we elucidated that the transcription factor JUN bound to the RGS4 promoter, driving its transactivation. However, OPD' interacted with JUN, attenuating its transcriptional activity and thereby disrupting RGS4 overexpression. In summary, our research revealed that OPD' bound with JUN, which in turn resulted in the suppression of transcriptional activation of RGS4, thereby eliciting cell cycle arrest and apoptosis in ATC cells. These findings could offer promise in the development of high‐quality candidate compounds for treatment in ATC.
- 17 August 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (16) , e70014
Open AccessOphiopogonin D′ inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling
Anaplastic thyroid cancer (ATC), an aggressive malignancy with virtually 100% disease‐specific mortality, has long posed a formidable challenge in oncology due to its resistance to conventional treatments and the severe side effects associated with current regimens such as doxorubicin chemotherapy. Consequently, there was urgent need to identify novel candidate compounds that could provide innovative therapeutic strategies for ATC. Ophiopogonin D′ (OPD'), a triterpenoid saponin extracted, yet its roles in ATC has not been reported. Our data demonstrated that OPD' potently inhibited proliferation and metastasis of ATC cells, promoting cell cycle arrest and apoptosis. Remarkably, OPD' impeded growth and metastasis of ATC in vitro and in vivo, displaying an encouraging safety profile. Regulator of G‐protein signalling 4 (RGS4) expression was significantly up‐regulated in ATC compared to normal tissues, and this upregulation was suppressed by OPD' treatment. Mechanistically, we elucidated that the transcription factor JUN bound to the RGS4 promoter, driving its transactivation. However, OPD' interacted with JUN, attenuating its transcriptional activity and thereby disrupting RGS4 overexpression. In summary, our research revealed that OPD' bound with JUN, which in turn resulted in the suppression of transcriptional activation of RGS4, thereby eliciting cell cycle arrest and apoptosis in ATC cells. These findings could offer promise in the development of high‐quality candidate compounds for treatment in ATC.
- Open Access
- 18 March 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (7) , e18182
BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability
Chromosome instability (CIN) is a common contributor driving the formation and progression of anaplastic thyroid cancer (ATC), but its mechanism remains unclear. The BUB1 mitotic checkpoint serine/threonine kinase (BUB1) is responsible for the alignment of mitotic chromosomes, which has not been thoroughly studied in ATC. Our research demonstrated that BUB1 was remarkably upregulated and closely related to worse progression‐free survival. Knockdown of BUB1 attenuated cell viability, invasion, migration and induced cell cycle arrests, whereas overexpression of BUB1 promoted the cell cycle progression of papillary thyroid cancer cells. BUB1 knockdown remarkably repressed tumour growth and tumour formation of nude mice with ATC xenografts and suppressed tumour metastasis in a zebrafish xenograft model. Inhibition of BUB1 by its inhibitor BAY‐1816032 also exhibited considerable anti‐tumour activity. Further studies showed that enforced expression of BUB1 evoked CIN in ATC cells. BUB1 induced CIN through phosphorylation of KIF14 at serine1292 (Ser1292). Overexpression of the KIF14ΔSer1292 mutant was unable to facilitate the aggressiveness of ATC cells when compared with that of the wild type. Collectively, these findings demonstrate that the BUB1/KIF14 complex drives the aggressiveness of ATC by inducing CIN.
- 18 March 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (7) , e18182
Open AccessBUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability
Chromosome instability (CIN) is a common contributor driving the formation and progression of anaplastic thyroid cancer (ATC), but its mechanism remains unclear. The BUB1 mitotic checkpoint serine/threonine kinase (BUB1) is responsible for the alignment of mitotic chromosomes, which has not been thoroughly studied in ATC. Our research demonstrated that BUB1 was remarkably upregulated and closely related to worse progression‐free survival. Knockdown of BUB1 attenuated cell viability, invasion, migration and induced cell cycle arrests, whereas overexpression of BUB1 promoted the cell cycle progression of papillary thyroid cancer cells. BUB1 knockdown remarkably repressed tumour growth and tumour formation of nude mice with ATC xenografts and suppressed tumour metastasis in a zebrafish xenograft model. Inhibition of BUB1 by its inhibitor BAY‐1816032 also exhibited considerable anti‐tumour activity. Further studies showed that enforced expression of BUB1 evoked CIN in ATC cells. BUB1 induced CIN through phosphorylation of KIF14 at serine1292 (Ser1292). Overexpression of the KIF14ΔSer1292 mutant was unable to facilitate the aggressiveness of ATC cells when compared with that of the wild type. Collectively, these findings demonstrate that the BUB1/KIF14 complex drives the aggressiveness of ATC by inducing CIN.
- 1 March 2021
- Published by Elsevier in Cancer Letters
- Vol. 501, 31-42
HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1
- 1 March 2021
- Published by Elsevier in Cancer Letters
- Vol. 501, 31-42
HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1